BioAlliance undeterred by move to shelve trial

France's BioAlliance Pharma says it's full steam ahead for its strategy to acquire complementary products for oncology and HIV, despite Immtech's decision to end a trial for pafuramidine--a program BioAlliance is partnered on. Immtech announced late Friday that it is shelving a safety study of pafuramidine after seeing reports of liver and kidney abnormalities. The drug was being tested for pneumonia in HIV patients and for African sleeping sickness.

- here's the release
- read the AFX report

Suggested Articles

Janssen’s BCMA-targeting CAR-T therapy eliminated tumors in 69% of patients with advanced multiple myeloma in a small phase 1 study.

In a study, BMS' CAR-T therapy banished tumors in more than half and shrank tumors in nearly three-quarters of relapsed blood cancer patients.

Novartis unveiled more data showing how its asthma combo QMF149 fared against the standard of care: a combination of the same types of drugs.